以影像学非强化病灶表现的高级别胶质瘤发生率:111例经手术病理诊断的非强化胶质瘤经验
回顾性分析2012年8月至2018年7月561例经组织诊断手术治疗的胶质瘤,其中111例(19.8%)术前MRI为非强化可疑胶质瘤病灶,最终病理诊断31例(27.9%)为高级别胶质瘤(WHO III或IV级)。年龄>60岁患者非强化病灶为高级别胶质瘤的比例为41.2%,高于<35岁患者的11.4%(Pearson卡方p<0.001)。作者建议对功能与健康状况良好、尤其>60岁的可疑胶质瘤患者,即使病灶非强化也应获取组织诊断。
要点
- 111例影像学非强化可疑胶质瘤中,27.9%最终病理为高级别胶质瘤(WHO III或IV级)。
- 年龄>60岁者非强化病灶为高级别胶质瘤的比例为41.2%,高于<35岁者的11.4%(p<0.001)。
- 作者建议功能与健康状况良好、尤其>60岁的可疑胶质瘤患者,即使非强化也应获取组织诊断。
核心结论
- 27.9%的非强化病灶最终病理诊断为高级别胶质瘤,比例具有临床意义。
- 作者建议对功能与健康状况良好、尤其年龄>60岁的可疑胶质瘤患者,即使病灶非强化也应获取组织诊断,以指导诊断及早期启动化疗和放疗。
研究设计与样本
- 回顾性分析2012年8月至2018年7月连续561例经组织诊断手术治疗的胶质瘤,其中111例为非强化病灶。
- 在非强化病灶中报告肿瘤标志物相对表达以探讨遗传相关性。
主要发现
- 561例手术治疗的胶质瘤中,111例(19.8%)术前MRI显示可疑胶质瘤的非强化病灶。
- 非强化病灶中31例(27.9%)分类为高级别胶质瘤(WHO III或IV级)。
- 年龄>60岁患者非强化病灶为高级别胶质瘤的比例为41.2%,年龄<35岁患者为11.4%(Pearson卡方p<0.001)。
- 二项逻辑回归显示年龄对非强化高级别胶质瘤中IDH突变存在显著的负向效应(p=0.007)。
关键数值与推荐
- 非强化病灶中高级别胶质瘤(WHO III或IV级)占27.9%(31/111)。
- 年龄>60岁者非强化病灶为高级别胶质瘤的比例为41.2%,<35岁者为11.4%(Pearson卡方p<0.001)。
- 二项逻辑回归显示年龄对非强化高级别胶质瘤中IDH突变有显著负向效应(p=0.007)。
临床怎么用
- 作者建议对功能与健康状况良好、尤其年龄>60岁的可疑胶质瘤患者,即使病灶非强化也应获取组织诊断,以指导诊断及早期启动化疗和放疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Although non-enhancing lesions suspicious for glioma are usually assumed to be low grade glioma (LGG), some high grade glioma (HGG) do not enhance, which may lead to a delay in biopsy and/or resection, diagnosis, and treatment initiation. Thus, there is a clear need for a large-sample study that quantifies the rate of malignant, non-enhancing gliomas. METHODS: We retrospectively reviewed our series of 561 consecutive surgically treated gliomas with tissue diagnosis, 111 of which were non-enhancing, to determine the prevalence of high-grade histology in radiographically presumed LGG. Relative expression of tumor markers were also reported for non-enhancing lesions to investigate genetic correlates. RESULTS: We identified 561 surgically treated gliomas with tissue diagnosis from August 2012 to July 2018 and found that 111 patients (19.8%) demonstrated non-enhancing lesions suspicious for glioma on preoperative MRI. Thirty-one (27.9%) of the non-enhancing lesions were classified as HGGs (WHO Grade III or IV). Non-enhancing lesions were four times more likely to be HGG in patients older than 60 years than patients younger than 35 years (41.2% vs. 11.4%, Pearson Chi2 p < 0.001). Binomial logistic regression showed a significant inverse effect of age on the presence of IDH mutation in non-enhancing HGGs (p = 0.007). CONCLUSION: A clinically significant proportion (27.9%) of non-enhancing lesions were found to be HGG on final pathologic diagnosis. Thus, in patients with good functional and health status, especially those older than 60 years, we recommend obtaining tissue diagnosis of all lesions suspected to be glioma, even those that are non-enhancing, to guide diagnosis as well as early initiation of chemotherapy and radiation therapy.
引用
- Eichberg DG, Di L, Morell AA, et al. Incidence of high grade gliomas presenting as radiographically non-enhancing lesions: experience in 111 surgically treated non-enhancing gliomas with tissue diagnosis. J Neurooncol. 2020. PMID: 32221785. doi:10.1007/s11060-020-03474-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。